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Whereas the pathological aspects of Gastric Adenocarcinomas (GACs) have been well defined, the actual
knowledge of its genesis and evolution remains to be translated to better diagnosis and to more effective
therapeutics. As a consequence, the current treatment modalities are not yet able to modify the natural history of
the disease, which still presents high mortality-rates worldwide. In this review we highlight the current status of
relevant epidemiologic, therapeutic and genomics aspects of GACs and point to some of the current knowledge
gaps that, if fully addressed, could contribute to a more effective treatment and better management of the patients
that suffer from this often-lethal disease.
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Gastric Cancer (GC) prevalence has shown a continuous
reduction in the last 70 years, but is still a common malig-
nancy and a frequent cause of cancer-related deaths
worldwide [1–4]. The new-cases/mortality rate is much
worse when compared to the more prevalent cancers:
about 90% of the 800,000 people that are diagnosed with
GC will die because of the disease [4–6]. In Brazil, after
excluding the non-melanoma skin cancers, GC is the sec-
ond more incident cancer type in men living in the North
(11.1:100,000) and Northeast (10.3:100,000) regions [7].
GC mortality has been dropping around the globe, in-
cluding Latin America, but the GC-related mortality
rates still remain unacceptable in many areas [8–11].
Whereas in countries like the United Kingdom and USA
the projected mortality rates for the year 2015 are below
5:100,000, it is above 10:100,000 in countries such as
Brazil, Colombia, Japan and Korea and even higher
(20:100,000) in Chile and the Russian Federation [11]. In
Brazil, gastric cancer remains as a serious public health
concern, especially in cities with high prevalence rates.
An example is the city of Belém (North of Brazil, in Pará
State) that shows disease prevalence above 20:100,000* Correspondence: emmanuel@cipe.accamargo.org.br
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average [7, 12–15].
GC is a disease that typically occurs between the 6th
and the 7th decade of life. Data from National Cancer
Institute (NCI - SEER, 2016) [16] show a median age at
diagnosis of 69 years with 81.5% of cases being diag-
nosed between 55 and 84 years old (Table 1). Usually,
the first GC more specific symptoms are perceived when
the disease is already advanced, leading to delayed diag-
nosis and reduced overall survival-rates. NCI’s recent
statistics also point out that most GCs (64%) are usually
diagnosed when the disease is already in the two final
stages [16], when the 5-years survival rates are already
much worse: 29.9% for lymph node disease and 4.5%, for
metastatic disease, compared to 65.4% for the early
detected, localized disease (Table 2).Molecular studies of gastric adenocarcinomas
The most prevalent GC-subtype is the GAC, which
comprises about 95% of the cases. GACs can be divided
as intestinal, diffuse, mixed and non-classifiable sub-
types [17]. Alternative GAC-classifications have been
proposed, and since 2014 molecular classifications start
being more widely adopted. Some articles suggested
classifying GACs as Epstein-Barr virus positive tumors
(EBV), lesions with microsatellite instability (MSI) and
those presenting chromosomal instability (CIN) [18–21].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Age distribution of new gastric cancer cases diagnosed
in the USA between 2008 and 2012










GE4GAC group Applied Cancer Research  (2017) 37:7 Page 2 of 9These classifications derived from large-scale genomic se-
quencing projects, which included hundreds of cases from
distinct populations, providing a more solid molecular
base for the disease classification.
Some of the current investigative projects include the
evaluation of exogenous and endogenous elements in
GAC development and progression, both very much re-
lated to epidemiologic aspects of the disease. Besides
diet, tobacco and alcohol usage, exogenous elements in-
clude the classic Helicobacter pylori & Epstein-Barr virus
infections, as well as the more innovative study of the
gastric microbiota and the role of drugs in GAC-
development.
The investigation of exogenous elements
Helicobacter pylori and the Epstein-Barr virus
The etiology of GCs and GACs results from a combined
interaction of diverse causal mechanisms that include
genetic susceptibility of the patient and exogenous ele-
ments, such as diet, tobacco and alcohol consumption,
as well as the history of infection by certain microorgan-
isms. As a general mechanism, it is believed that these
elements act over the gastric mucosa leading to chronic
inflammation, one of the first carcinogenic steps.
One of the most important causes of inflammation of
the gastric mucosa is the infection by Helicobacter pylori
(Hp). Hp is a gram-negative bacillus, present in about
50% of the world population [22]. Warren & Marshall
[23] were the first to suggest the GAC:Hp link, and this
awarded them with the Nobel Prize of Medicine in 2005.Table 2 Distribution of stomach cancer cases at diagnosis and





Localized disease 26 65.4
Lymph node disease 29 29.9
Metastatic disease 35 4.5
Data derived from cases diagnosed and treated in the USA between 2005 and
2011. Source: SEER, 2016The recognition that Hp can cause GAC led WHO to
consider Hp as a carcinogenic agent [24] and to promote
its eradication as one of the strategies to prevent the dis-
ease, even after tumor resection [25, 26].
Chronic gastritis, involving the activation of cellular
and humoral responses in the gastric mucosa is one of
the first signs of Hp infection [27]. Hp appears to be
more prevalent in the Lauren’s intestinal GAC subtype
[28], which is characteristic of the CIN-TCGA classifica-
tion [21]. When Hp evades this rich immunological re-
sponse it leads to persistent infection and the chronic
inflammation may evolve to a histologic progression first
characterized as an unspecific chronic gastritis, with
progressive gastric damage and atrophy of the mucosa.
This is followed by the replacement of the normal
glandular architecture by an intestinal-type metaplastic
mucosa sometimes with the progressive development of
cellular atypia (dysplasia), which culminate with GAC
[29]. The virulence of the Hp-strain seems to correlate
with the degree of this inflammatory process [30].
Another GAC-associated agent is the EBV herpesvirus
(HHV-4), a double-stranded DNA virus with a 172,000
bases genome. EBV infection is also acquired by infants
and when persistent may cause chronic gastric inflam-
mation and cancer. Its oncogenic pathways involve the
expression of membrane and viral nuclear antigens that
interact with tumor suppressor genes and disturb many
signaling pathways [31]. In Brazil, the EBV-associated
GAC (GAC-EBV) has a prevalence of 4.7 to 12% [32–34]
in agreement with the worldwide range of ~7% [35]. The
GAC-EBV is a unique clinicopathological entity: it appears
to be more prevalent in men, is usually found in the prox-
imal region of the stomach and is frequently present in
younger subjects [35, 36]. A recent publication found
PIK3CA mutations in about 80% of GAC-EBV [20], and
papers have reported that GAC-EBV patients usually have
less lymph node disease but with contradictory prognosis
reports [35–38].
The gastric microbiota
The human microbiota is the set of microorganisms that
live in and on us. Recent estimates suggest that our
microbiota is composed of ~39 trillion bacteria to about
30 trillion human cells, a roughly 1:1.3 ratio [39]. The
microbiota can be perceived as an intermediate element
between exogenous and endogenous factors, which helps
metabolize diet components, acts as a physical barrier
against the colonization by potentially pathogenic micro-
organisms and contributes to the development and mat-
uration of our immune system [40–42].
A recent study of our group showed that the con-
sumption of alcohol and tobacco severely reduces the
number of bacterial species found in the oral mucosa
[43]. Since these drugs appear to have a role in GACs,
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important for disease development.
For a long period there was the belief that the stomach
should be an essentially sterile cavity, a sort of acid bar-
rier that would block the transfer and spread of microor-
ganisms between the lower and the upper digestive tract
[44]. However, as described above, the presence of Hp
and EBV not only demonstrates the ability of some life
forms to survive and to colonize the stomach, but also
demonstrates a role of microorganisms in GAC develop-
ment. In this context it is possible that other microor-
ganisms could be also associated with GAC.
Up to now very few studies have focused on the ana-
lysis of the gastric microbiota in GACs. Stearns et al.,
2011 [45] evaluated the oral, stomach, duodenum and
the fecal microbiota of four individuals, using the se-
quencing of the V3-region of the 16S-rDNA bacterial
gene. The result suggests a continuum in the microbiota
along the gastrointestinal tract, with some microorgan-
isms being restricted to particular organs. They also
showed the stomach to have the lowest bacteria diversity
among all body regions evaluated. A more recent study
[46] evaluated the gastric microbiota in individuals diag-
nosed with non-atrophic gastritis, intestinal metaplasia,
and intestinal-type gastric cancer. The findings of this
study were limited by the low number of individuals (n =
5/group) and the methods used (a small set of
hybridization of probes), but suggested the microbiota di-
versity to be consistently reduced in GACs. More recently,
the effects of subtotal gastrectomy on the microbiota
present in the stomach tissue of six GAC patients were
evaluated [47]. They found that bacterial diversity in-
creased after surgery and that Ralstonia and Helicobacter
decreased in abundance after tumor excision. However,
their study was also limited by the number of individuals
(n = 6) sampled. In a recent study [48], the gastric micro-
biota of four groups was analyzed; control Hp + (n = 16),
control Hp - (n = 13), cancer Hp + (n = 15), cancer Hp -
(n = 19). No differences in diversity or phyla/genera
abundances were observed between the groups, but the
study had a major limitation: a shallow sequencing depth
with an average of only 4,074 sequences/sample. In this
sense, larger studies and more comprehensive approaches
are needed to determine the role the microbiota plays in
GACs.
Diet, tobacco and alcohol
Some authors showed that GAC-patients have a diet
lacking complex carbohydrates, with high consumption
of eggs, and low frequency of fresh fruits and vegetables
[49–52]. The low consumption of fruits has been associ-
ated with the occurrence of pre-neoplastic lesions and
higher GAC and the use of sodium chloride as a food-
preservative has been found to be positively associatedwith the disease [49–50]. As suggested [51], diets that
are rich in antioxidants, such as β-carotene and ascorbic
acid, appear to help reducing the incidence of GACs.
Tobacco use is an important risk factor for GACs [53, 54].
A possible correlation of GAC and alcohol-consumption
also appears to exist, since frequent alcohol consumption
leads to chronic gastritis, considered as one of the first gas-
tric carcinogenesis steps [51]. A meta-analysis review [55]
detected a 20% increment in the incidence of GACs in indi-
viduals that drink above four alcohol-doses/day.
Studies of endogenous elements
Ethnic aspects & genomic ancestry
The incidence of GACs is high in the Middle East and
in countries such as Brazil, Peru, Japan, the Koreas and
China and the Russian Federation [56]. However, the
GAC-related mortality varies in these regions, and it is
not a simple reflex of economic discrepancies among
these countries. Interestingly, the GAC-associated mor-
tality for Japanese-descendants in Brazil is lower than
that observed in Japan, but still 50% higher than that
seen in Brazilians with no Japanese ancestry [57, 58].
Ethnic aspects also appear to play a major role in disease
prognosis and response to treatment. The overall 5-year
survival rate among Japanese patients, considering all
clinical stages, is of 40–60%, a sharp difference compar-
ing to only 15–30% in the USA and Europe [59, 60]. At
first sight this could be associated to an early diagnosis
in a cultural milieu more alert to this neoplasia, or to
better or more aggressive surgical approaches performed
in Japan [61]. However, studies with Japanese-
descendants living out of Japan indicate that ethnic is-
sues play a major role. Taking into account the elevated
ethnic admixture of some populations, including Brazi-
lians, the precise determination of ancestry is important
for future studies of GAC predisposition and prognosis.
A recent study evaluated 13,084 GAC patients diag-
nosed between 1988 and 2006, registered in Los Angeles,
US and categorized as white (39%), Hispanic (28%),
Asians (22%), African-Americans (11%) and others (2%).
The study found a much superior overall survival for
Asians (16.3 months), when compared to the other
groups (8.7–7.9 months, p < 0,001) [62]. As this study
was done in the United States, it contradicts the hypoth-
esis that Asian patients have a better outcome mainly
due to distinct surgical treatment compared to Western
patients.
The response to certain antineoplastic agents and tar-
geted therapies also diverge between patients of different
geographic-regions/ethnic background. As an example,
the AVAGAST study, that evaluated the role of an anti-
angiogenic monoclonal antibody (bevacizumab) plus
chemotherapy in the treatment of metastatic GC, found
different responses between Asians and US patients [62].
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vival increment for Asians (13.9 months for patients treated
with chemotherapy + bevacizumab × 12.1 months for those
treated with chemotherapy + placebo; HR 0.97 IC 95%
0.75–1.25) it was more effective for US patients (11.5 months
for chemotherapy + bevacizumab × 6.5 months for chemo-
therapy + placebo; HR 0.63 IC 95% 0.43–0.94). Unfortu-
nately, survival rates for both US groups were worse than
for Asians, emphasizing that ethnic/ancestry issues are
relevant for predicting tumor behavior and treatment
response [62].
Genetic and genomics aspects
Whereas most cases of GAC occur after 55 years of age,
data from SEER, 2016 [16] shows that a small fraction
(6.2%) of the USA patients present the disease before
age 45 (Table 1). The biological and clinicopathological
features of the Early Onset GAC (EOGAC) are remark-
ably distinct from the sporadic GAC of older patients,
suggesting these to be distinct entities [63, 64].
While endogenous factors such as germline mutations
appear to impact the EOGAC more severely, exogenous
factors are probably more relevant for the sporadic
disease. After observing the occurrence of germline E-
cadherin mutations (CDH1) in hereditary diffuse GAC,
and the earlier onset of these tumors, groups start inves-
tigating this mutation in EOGAC. Kim et al. found only
2/25 EOGAC-patients to carry CDH1-mutaions patients
(<50 years-old) [63], and Corso et al., 2011 [65] obtained
similar data (2/21) for diffuse GACs. After reviewing the
literature these authors found 7.2% of EOGAC carrying
CDH1 mutations, but only 2.3% of EOGAC appear to
have mutations that are highly likely to be pathogenic,
and those were found in patients diagnosed before the
age of 35 [66].
Diffuse hereditary GACs have particular clinical
aspects, and patients carrying these tumors have been
frequently identified with CDH1 mutations or promoter-
methylation [67–70]. Whereas the non-symptomatic in-
dividuals carrying CDH1 mutations present a high risk
of developing a diffuse-type GAC throughout life, endo-
scopic screening is usually not useful for early screening
since the stomach has a normal appearance, and biopsies
often fail to demonstrate malignancy. Therefore, pre-
ventive gastrectomy has been frequently suggested [71].
In Brazil, GAC is the most frequent non-colonic
tumor type identified in the patients harboring the
hereditary nonpolyposis colorectal cancer (HNPCC) syn-
drome and hereditary colorectal cancer [72, 73]. GAC is
also present in a number of other syndromes including:
− Hereditary Breast and Ovary Cancer (HBOC), related
to BRCA1 and BRCA2 mutations; −Familial
Adenomatous Polyposis (FAP); − Peutz-Jeghers
Syndrome (associated with germline STK11 mutations);− Juvenile Polyposis Syndrome, associated to SMAD4
and BMPR1A mutations; − Li-Fraumeni Syndrome
(LFS), characterized by germline mutations of the TP53
gene.
The most relevant molecular alterations identified in
GACs
GAC is a disease with a complex pattern of mutational,
structural, karyotypic, as well as gene and protein ex-
pression. Besides this, chromosomal and DNA microsat-
ellite instability have been frequently demonstrated in
these tumors [74, 75].
Alterations in gene-expression patterns in the different
carcinogenic steps of epithelial cell transition, going
from inflammation to invasive neoplasia, have been re-
cently investigated by large-scale next-generation RNA
sequencing (RNA-Seq) and allowed the definition of
gene signatures for distinct histological grades and histo-
logical types of GACs [21].
Holbrook et al. evaluated a gene panel composed of
384 genes frequently mutated in cancer, in an attempt to
provide faster clinical applications in precision medicine
and found frequent alterations in genes of the WNT
pathway, tyrosine receptor kinases, as well as genes en-
coding proteins related to cell-cycle, DNA-repair and
epithelial-mesenchymal-transition. From this data, the
authors estimated that therapies already approved, or
currently under development, may benefit 22% of the
GACs that carry mutations in the target genes of these
drugs [76].
In 2014, The Cancer Genome Atlas (TCGA) consortium
published the study of 295 pairs of tumor x non-tumor
gastric samples. This consortium employed six distinct
analysis platforms - including mRNA & miRNA expres-
sion studies, DNA methylation, copy-number variation
and whole exome sequencing – in an attempt to define a
consistent molecular classification of GAC [21]. The re-
sults suggest the existence of 4 major tumor-types: EBV+
(26/295), MSI+ (64/295), GS (Genomically Stable, 58/295)
and CIN (147/295). EBV+ tumors showed high frequency
of PIK3CA mutations (80%) and were usually more fre-
quently located in the fundus or gastric body (62%, p =
0.02); MSI+ tumors frequently occur in patients of more
advanced age (>72 years-old, p = 5 × 10−5), an opposite
trend to that seen for GS tumors (59 years-old, p = 4 × 10
−7). Also, MSI+ tumors showed a higher frequency among
diffuse-type tumors (40/55 = 73%, p = 8 × 10−7). RNA-Seq
data found 4 mRNAs- and 5 miRNA-sets capable of distin-
guishing these molecular GAC-subtypes, and revealed new
splicing isoforms of the MET gene, which showed to be as-
sociated with a higher expression of this proto-oncogene.
In this same year, Kakiuchi et al. performed WES of 30
diffuse-type GAC samples. Their findings pointed to an
elevated frequency of RHOA-mutations that apparently
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is a member of the RHO-GTPases family. The data was
confirmed in a second set of samples and indicates that
25% of the diffuse GACs carry these mutations and may
benefit of a new therapeutic approach [20]. This study
also showed that, in most cases, the relatively common
mutations found in RHOA and HER2, appear to be
mutually exclusive. This suggests that RHOA could be a
relevant target for patients that have no HER2 amplifica-
tion [20].
In another recent publication, the whole genome se-
quencing (WGS) of 100 pairs of normal/tumor gastric
tissue samples as well as studies of CNV, global methyla-
tion and RNA-Seq were reported. The finding of recur-
rent mutations in RHOA was confirmed and showed to
be restricted to GACs of the diffuse-type (14.3%).
Driver-genes were identified for all the major GAC-
subtypes, and validated in independent cohorts. Genes
relevant for GAC-biology were confirmed, including
TP53, ARID1A and RHOA, and new driver genes were
also identified (MUC6, CTNNA2, GLI3, RNF43 and
others) [19].
When taken together, this recent literature shows that
molecular classifications could be useful tools for the
study of GACs, with direct applicability for cancer diag-
nosis for the search of new therapeutic targets. However,
as these studies involved a relatively small number of
tumors of few population groups – only Europeans,
North-Americans and Asians – it is not possible yet to
claim that the full GAC mutational-spectrum has been
fully covered. The molecular profiles identified up to
now were not confirmed in highly admixed populations,
such as the Brazilian, and it is certain that the inclusion
of genetically admixed individuals may reveal new
molecular markers – a consequence of our genetic com-
plexity [77].
Molecular mechanisms associated with tumor
progression and treatment resistance:
identification of biomarkers
Treatment response and disease outcomes in GACs
Even neoplasms with the same histological subtype,
grade, stage and treatment have heterogeneous clinical
outcome, thus suggesting that individual susceptibility
must be searched in molecular grounds.
Perioperative chemotherapy associated with surgery is
one of the main strategies in the treatment of stage II and
III GAC patients. In this context, the addition of some cy-
cles of chemotherapy before and after surgery reduces the
risk of tumor relapse and death [78, 79]. However, chemo-
therapy response is heterogeneous and so far there are no
standard methods to assess it. The complete absence of
viable cells in resected stomach and lymph nodes is a clear
signal of response to chemotherapy and correlatespositively with survival – unfortunately, this full response
is only seen in less than 10% of the patients [80]. Thus,
the identification of new markers of response to neoadju-
vant chemotherapy may help to improve treatment
decisions and outcomes in patients with potentially
curable disease.
The treatment of patients with metastatic or relapsed
GAC is another huge challenge. Surgery and radiother-
apy have limited indication in this scenario and patients
usually receive systemic treatment with platins, fluoro-
pyrimidines, taxanes and topoisomerase inhibitors. In
2010 trastuzumab was the first target-specific therapy
associated with a survival benefit in advanced gastric
cancer patients [81]. It was incorporated in clinical prac-
tice as part of first-line regimen in combination with
chemotherapy, but it’s benefit is restricted to ~20% of
cases that are positive for the amplification of ERBB2/
HER2 [82]. Ramucirumab is an anti-VEGFR2 monoclo-
nal antibody that inhibits VEGF signaling and angiogen-
esis. In 2014, two randomized trials demonstrated the
activity of ramucirumab in second line, either as mono-
therapy or associated with paclitaxel [83, 84]. More
recently, a double-blind randomized study evaluated the
activity of apatinib (another VEGFR2-inhibitor) in 267
heavily pretreated patients with advanced GACs. The
study reported a modest but statistically significant im-
provement in progression free survival and overall sur-
vival in apatinib treated patients compared to placebo
[85]. Taken together, these trials demonstrate that anti-
angiogenic drugs could be relevant in the treatment of
advanced gastric cancer.
Recent publications suggest that new immunotherapeu-
tic strategies may be promising opportunities for GAC pa-
tients. A recent study found the expression of PD-L1 in
51% of 132 samples of gastric cancer tumor, derived from
Chinese patients. Whereas these authors found no rela-
tionship between PD-L1 expression and many clinicopath-
ological variables (including age, gender, clinical stage,
location and histological differentiation), PD-L1 positive
patients had significantly poorer 5-years survival rates
than negative patients (51% × 83.1% respectively, P <
0.001) [86]. Preliminary clinical data from a phase I trial
with the anti-PD1 antibody pembrolizumab revealed an
overall response rate of 22% and a median duration of re-
sponse of 6 months in a chemotherapy refractory popula-
tion of GAC patients [87].
At this moment, all agents used in the management of
metastatic GAC patients bring a perspective of tempor-
ary disease control but not cure, and the median survival
is still below 1 year. They all have one point of conver-
gence: resistance. Understanding the molecular events
that drive the disease may help to identify the best re-
sponders to each agent (including immunotherapy) and
to use resources and drugs more efficiently.
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Tumor dissemination requires the presence of cells that
leave the primary site and circulates in blood. The cap-
ability of these cells to form tumors has been demon-
strated and the number of CTCs per mL of blood has
prognostic value [88]. It is known today that CTCs have
‘organ-preferences’ allowing a selective colonization
process compatible with the historic concept of “seed
and soil”, first suggested by Stephen Paget in 1889.
If we consider that the tumors - and the CTCs that they
originate from - are immunologically distinct of the non-
tumor tissues, the requirement to escape the host’s im-
mune response is a constant pressure. One of the possible
escape mechanisms is the establishment of groups of
‘small tumors’ or micro-emboli: aggregates of 5–10 cells
that travel together in the blood, reach distant organs and
promotes the recruiting of pro-angiogenic factors and the
expression of new surface markers [89]. It is estimated
that these CTC-clusters represent only about ~3% of the
total CTCs found in the blood. However, it has recently
demonstrated that they are responsible for the formation
of more then 50% of the metastasis [90], making their
presence a major element in invasive metastatic tumors
[90, 91]. Therefore, it is possible that the study of CTCs
could contribute more to the definition of anti-metastatic
therapies than the study of the primary tumors.
Few studies, involving small patient groups, have evalu-
ated the detection and the qualitative analysis of CTCs in
GACs. Using the CellSearch® system authors reported the
detection of CTCs in 14% of patients with non-metastatic
GACs and in 55% of patients with metastatic disease (≥2
CTCs/7.5 mL of blood) [92]. In agreement with studies of
other tumors, elevated concentrations of CTCs (≥4 CTCs/
7.5 mL of blood) during treatment (2 to 4 weeks after the
start of chemotherapy) were associated with worst prog-
nosis of GACs (average survival of 3.5 × 11.7 months).
CTCs also appear to impact chemotherapy response. A
group in Japan studied 52 patients with advanced GAC
and found an inverted relation between CTC-levels and
the efficacy of distinct chemotherapeutic regimens [93].
Two recent metanalyses involving CTCs and the presence
of specific circulating miRNAs suggest that patients posi-
tive for both had reduced disease-free survival, as well as a
reduced overall survival [94, 95].
Extracellular Vesicles (EVs)
Extracellular Vesicles (EVs) are structures derived from
cell membranes, secreted by many cell types, and carry a
cargo of proteins, mRNAs, microRNAs, other non-coding
RNAs and apparently some DNA [96]. EVs are an ex-
ample of a well-organized system of cell-cell communica-
tion in physiologic and pathologic conditions [97].
Many studies have suggested that EVs are capable of
transferring molecular information from the tumormicroenvironment to distant sites, which confers them a
pivotal role during tumor progression [98, 99]. The most
studied groups of EVs are the microvesicles, formed
through the outward blabbing of the plasma membrane
(average size ranging from 0.1 to 1 μm) and the exo-
somes, smaller vesicles (30 to 150 nm) formed by the
endosome pathway and released after the fusion of
multi-vesicular bodies with the cell membrane [100].
Proteins and lipids present in the surface of EVs allow
them to recognize certain molecules in the membrane of
the target cells, thereby providing a very efficient signal-
ing mechanism, and allowing the release of the EV’s
content that seem to trigger biological alterations in the
receptor cell [101]. Our group has recently shown, using
an in vitro model of breast cells, that the overexpression
of only HER2 (which is also very important in GACs) in-
duces dramatic proteome alterations in the EVs. Import-
antly, we found that EVs carry a heavy load of HER2 and
are thus potentially able to disseminate this oncogene to
other tissues and cells [102]. This is relevant in a sce-
nario of tumor heterogeneity, where the amplification of
HER2 is far from being homogeneous [82, 103], and can
possibly impact the efficacy of Traztuzumab-treatment,
as EVs may act as sponges sequestering the drug and re-
ducing its tumor-availability. This finding may be rele-
vant here, due to the use of traztuzumab in GAC-
patients with advanced disease, as previously mentioned.
The signals induced after the release of EVs in the
body fluids of cancer patients can be related to a
series of relevant aspects of tumor progression, in-
cluding cell adhesion and survival, proliferation, inva-
sion, inflammation, modulation of immune response,
thrombosis and angiogesis [104]. Recent studies have
shown that EVs have a key role in the development
of the pre-metastatic niche, by promoting a commu-
nication between tumor and non-tumor cells and cre-
ating a favorable microenvironment adequate to the
arrival and survival of circulating cancer cells in this
new environment [98].
The roles of the EVs in GAC have been little studied.
It is known that EVs secreted by gastric cancer cell lines
promote the activation of the PI3K-AKT pathway and
induce cell proliferation [105]. Li et al., 2014 recently
suggested exosomes might serve as a protective struc-
ture, preserving useful biomarkers, such as long noncod-
ing RNAs [106]. The quantitative analysis of EVs in the
blood of GAC-patients showed these vesicles to be more
concentrated in patients with more advanced GAC, and
the increment of the proteins HER2/neu, MAGE-1, c-
MET e EMMPRIN, when compared to controls [104].
Since EVs carry molecular signatures of the tumors, the
systematic mapping of these molecules and their target
cells/tissues, can potentially contribute for the identifica-
tion of biomarkers and drug targets in cancer.
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Gastric adenocarcinoma remains as a very important and
challenging health issue in the world. Whereas its inci-
dence curve showed a descendent slope in more devel-
oped nations, declining from 3 to 5% per year, it remained
stable in the last 15 years with no recent trends of further
reductions. In the underdeveloped nations of South-
America and Asia this reduction had a slower pace of only
about 1% per year. It should be noted that the mortality
reduction achieved today derives more from earlier diag-
nosis than from the development of new therapeutic ap-
proaches or from advances in our knowledge of the
molecular basis of the disease. Therefore, whereas the epi-
demiology of GACs must be continuously revisited and
updated, the need for new therapeutic targets still lingers.
Better diagnostic and prognostic markers are needed, and
will help define disease-subgroups and pave the way to a
deeper knowledge of the disease.
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